Out of the Crisis #5, ANA Therapeutics: a possible COVID-19 treatment and prophylactic
Startup Lessons Learned
MAY 27, 2020
51:36) Scientific background on niclosamide, what we know about how it works to stop viral replication. (52:48) But you emailed your investors, you got a sense that there was some interest there. And often what we're seeing in these hydroxychloroquine studies is a big ratcheting of a typical dose. And I just felt sick.
Let's personalize your content